ReviewFrontiers in immunology2026
Immunological and pathological roles of Siglecs: a molecular review.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- NKR-P1A/CD161: A Multifunctional Immune Receptor at the Crossroads of Antitumor Immunity.Biomolecules · 2026Review
- Neutrophil CEACAMs and the Inflammatory Response toJournal of innate immunity · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Siglecs are sialic acid-binding immunoglobulin-like receptors that regulate immune responses through inhibitory and activating signaling pathways. By recognizing sialoglycan ligands, they modulate innate and adaptive immunity, and their dysregulation is increasingly linked to diverse human diseases. This review highlights the roles of human Siglecs in disease pathogenesis, including cancer, autoimmune and inflammatory disorders, neurodegeneration, and infections. We summarize key regulatory mechanisms such as transcription factors, microRNAs, and protein interactions and outline major signaling pathways underlying Siglec-mediated immune modulation. At the molecular level, Siglecs signal via ITIM dependent inhibitory pathways SHP-1/SHP-2 or ITAM/DAP12-associated activation SYK/MAPK, maintaining immune homeostasis. Targeting the Siglec glycan axis offers promising therapeutic opportunities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.